何星晓,黄凯璇,覃后继,吕建楠

人类免疫缺陷病毒（Human immunodeficiency virus，HIV）和乙型肝炎病毒（Hepatitis B virus，HBV）共感染较为常见，共感染通常导致疾病的加速进展。对于HIV/HBV共感染者的治疗，各大指南均推荐使用包含具有双重抗HIV/HBV活性药物组成的联合抗逆转录病毒治疗（Antiretroviral therapy，ART）方案。这些药物包括恩曲他滨、拉米夫定、替诺福韦酯和替诺福韦艾拉酚胺，它们都是核苷类逆转录酶抑制剂，然而，长期应用的耐药性和副作用等问题备受瞩目。本文概述了当前为解决这一问题而进行研究的一些西药的机制、安全性和有效性以及中医药在这一领域的研究进展。

HIV；乙肝病毒；合并感染；抗病毒；双活性药物；综述

[1] SINGH K P, CRANE M, AUDSLEY J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment[J]. AIDS, 2017,31(15): 2035-2052. [2] NAING C, POOVORAWAN Y, TONG K S. Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis[J]. BMC Infect Dis, 2018,18(1): 564. [3] LAI C L, YUEN M F. Management of chronic hepatitis B in patients from special populations[J]. Cold Spring Harb Perspect Med, 2015,5(6). [4] SORIANO V, BARREIRO P, BENITEZ L, et al. New antivirals for the treatment of chronic hepatitis B[J]. Expert Opin Investig Drugs, 2017,26(7): 843-851. [5] MENNE S, TUMAS D B, LIU K H, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B[J]. J Hepatol, 2015,62(6): 1237-1245. [6] JANSSEN H, BRUNETTO M R, KIM Y J, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B[J]. J Hepatol, 2018,68(3): 431-440. [7] BONI C, VECCHI A, ROSSI M, et al. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues[J]. Gastroenterology, 2018,154(6): 1764-1777. [8] OFFERSEN R, NISSEN S K, RASMUSSEN T A, et al. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells[J]. J Virol, 2016,90(9): 4441-4453.[9] TSAI A, IRRINKI A, KAUR J, et al. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy[J]. J Virol, 2017,91(8). [10] RAM R R, DUATSCHEK P, MARGOT N, et al. Activation of HIV-specific CD8(+) T-cells from HIV+ donors by vesatolimod[J]. Antivir Ther, 2020,25(3): 163-169. [11] LIM S Y, OSUNA C E, HRABER P T, et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy[J]. Sci Transl Med, 2018,10(439). [12] BORDUCCHI E N, LIU J, NKOLOLA J P, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys[J]. Nature, 2018,563(7731): 360-364. [13] LI S Y, LI H, XIONG Y L, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017,24 Suppl 1: 12-20. [14] HARDY G A, SIEG S, RODRIGUEZ B, et al. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers[J]. PLoS One, 2013,8(2): e56527. [15] HUA S, VIGANO S, TSE S, et al. Pegylated Interferon-alpha-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients[J]. Clin Infect Dis, 2018,66(12): 1910-1917. [16] D'OFFIZI G, GIOIA C, CORPOLONGO A, et al. An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects[J]. Int J Immunopathol Pharmacol, 2007,20(3): 473-485. [17] GARRIDO C, ABAD-FERNANDEZ M, TUYISHIME M, et al. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo[J]. J Virol, 2018,92(12). [18] JONES R B, MUELLER S, O'CONNOR R, et al. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes[J]. PLoS Pathog, 2016,12(4): e1005545. [19] WALTER J, GHOSH M K, KUHN L, et al. High concentrations of interleukin 15 in breast milk are associated with protection against postnatal HIV transmission[J]. J Infect Dis, 2009,200(10): 1498-1502. [20] SWAMINATHAN S, QIU J, RUPERT A W, et al. Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation[J]. PLoS One, 2016,11(11): e167091. [21] HAN W, NI Q, LIU K, et al. Decreased CD122 on CD56(dim) NK associated with its impairment in asymptomatic chronic HBV carriers with high levels of HBV DNA, HBsAg and HBeAg[J]. Life Sci, 2018,195: 53-60. [22] Di SCALA M, OTANO I, GIL-FARINA I, et al. Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice[J]. J Virol, 2016,90(19): 8563-8574. [23] YIN W, XU L, SUN R, et al. Interleukin-15 suppresses hepatitis B virus replication via IFN-beta production in a C57BL/6 mouse model[J]. Liver Int, 2012,32(8): 1306-1314. [24] MARGOLIS D, HEREDIA A, GAYWEE J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity[J]. J Acquir Immune Defic Syndr, 1999,21(5): 362-370. [25] UI H, ASANUMA S, CHIBA H, et al. Mycophenolic acid inhibits syncytium formation accompanied by reduction of gp120 expression[J]. J Antibiot (Tokyo), 2005,58(8): 514-518. [26] MARGOLIS D M, MUKHERJEE A L, FLETCHER C V, et al. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection[J]. AIDS, 2007,21(15): 2025-2032. [27] JURRIAANS S, SANKATSING S U, PRINS J M, et al. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil[J]. AIDS, 2004,18(11): 1607-1608. [28] GONG Z J, De MEYER S, CLARYSSE C, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro[J]. J Viral Hepat, 1999,6(3): 229-236.[29] WU J, XIE H Y, JIANG G P, et al. The effect of mycophenolate acid on hepatitis B virus replication in vitro[J]. Hepatobiliary Pancreat Dis Int, 2003,2(3): 410-413. [30] YING C, De CLERCQ E, NEYTS J. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus[J]. Antiviral Res, 2000,48(2): 117-124. [31] PAN Q, van VUUREN A J, van der LAAN L J, et al. Antiviral or proviral action of mycophenolic acid in hepatitis B infection?[J]. Hepatology, 2012,56(4): 1586-1587. [32] CHENG Z, LIN P, CHENG N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases[J]. Front Med (Lausanne), 2021,8: 713981. [33] BANGA R, PROCOPIO F A, NOTO A, et al. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals[J]. Nat Med, 2016,22(7): 754-761. [34] CUBAS R A, MUDD J C, SAVOYE A L, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection[J]. Nat Med, 2013,19(4): 494-499. [35] THIBULT M L, MAMESSIER E, GERTNER-DARDENNE J, et al. PD-1 is a novel regulator of human B-cell activation[J]. Int Immunol, 2013,25(2): 129-137. [36] FROMENTIN R, DAFONSECA S, COSTINIUK C T, et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals[J]. Nat Commun, 2019,10(1): 814. [37] LAKE A C. Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy[J]. AIDS, 2017,31(15): 2115-2118. [38] BUROVA E, HERMANN A, WAITE J, et al. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice[J]. Mol Cancer Ther, 2017,16(5): 861-870. [39] ULDRICK T S, GONCALVES P H, ABDUL-HAY M, et al. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study[J]. JAMA Oncol, 2019,5(9): 1332-1339. [40] WEN X, WANG Y, DING Y, et al. Safety of immune checkpoint inhibitors in Chinese patients with melanoma[J]. Melanoma Res, 2016,26(3): 284-289. [41] PANDEY A, EZEMENARI S, LIAUKOVICH M, et al. A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B[J]. Case Rep Oncol Med, 2018,2018: 5985131. [42] VELU V, SHETTY R D, LARSSON M, et al. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options[J]. Retrovirology, 2015,12: 14. [43] WYKES M N, LEWIN S R. Immune checkpoint blockade in infectious diseases[J]. Nat Rev Immunol, 2018,18(2): 91-104. [44] RAY A S, FORDYCE M W, HITCHCOCK M J. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus[J]. Antiviral Res, 2016,125: 63-70. [45] CORY T J, MIDDE N M, RAO P, et al. Investigational reverse transcriptase inhibitors for the treatment of HIV[J]. Expert Opin Investig Drugs, 2015,24(9): 1219-1228. [46] LANIER E R, PTAK R G, LAMPERT B M, et al. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV[J]. Antimicrob Agents Chemother, 2010,54(7): 2901-2909. [47] PAINTER G R, ALMOND M R, TROST L C, et al. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections[J]. Antimicrob Agents Chemother, 2007,51(10): 3505-3509. [48] TREPANIER D J, URE D R, FOSTER R T. In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B[J]. Pharmaceutics, 2017,9(4). [49] PHILLIPS S, CHOKSHI S, CHATTERJI U, et al. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production[J]. Gastroenterology, 2015,148(2): 403-414. [50] HANSSON M J, MOSS S J, BOBARDT M, et al. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection[J]. Chem Biol, 2015,22(2): 285-292. [51] GALLAY P, URE D, BOBARDT M, et al. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice[J]. PLoS One, 2019,14(6): e217433. [52] KUO J, BOBARDT M, CHATTERJI U, et al. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models[J]. J Pharmacol Exp Ther, 2019,371(2): 231-241. [53] 刘颖, 邹雯, 王健. 中医药治疗艾滋病 30 年回顾与展望[J]. 中国艾滋病性病, 2019,25(08): 771-772. [54] 陈寅萤, 王忠, 南景一, 等. 中医药治疗慢性乙型肝炎的研究进展[J]. 世界中西医结合杂志, 2020,15(04): 779-784. [55] ISLAM S S, NARGIS R R, QAIS N. Medicinal herbs and their metabolites with biological potential to protect and combat liver toxicity and its disorders: A review[J]. Heliyon, 2024,10(3): e25340. [56] SINGH S, SHARMA S, SHARMA H. Naturally Occurring Herbs and their Bioactive Metabolites: Potential Targets and Signaling Pathways of Antiviral Agents[J]. Endocr Metab Immune Disord Drug Targets, 2023,23(12): 1505-1537. [57] JOCELYN, NASUTION F M, NASUTION N A, et al. HIV/AIDS in Indonesia: current treatment landscape, future therapeutic horizons, and herbal approaches[J]. Front Public Health, 2024,12: 1298297. [58] BACHAR S C, MAZUMDER K, BACHAR R, et al. A Review of Medicinal Plants with Antiviral Activity Available in Bangladesh and Mechanistic Insight Into Their Bioactive Metabolites on SARS-CoV-2, HIV and HBV[J]. Front Pharmacol, 2021,12: 732891. [59] SINGH S, MURTI Y, SEMWAL B. Antiviral Activity of Natural Herbs and their Isolated Bioactive Compounds: A Review[J]. Comb Chem High Throughput Screen, 2023. [60] 卢平. 艾滋病患者抗病毒治疗效果的影响因素分析[J]. 青岛医药卫生, 2024,56(02): 89-92. [61] CHANG J S, WANG K C, LIU H W, et al. Sho-saiko-to (Xiao-Chai-Hu-Tang) and crude saikosaponins inhibit hepatitis B virus in a stable HBV-producing cell line[J]. Am J Chin Med, 2007,35(2): 341-351. [62] CHANG J, WANG K, LIU H, et al. Sho-saiko-to (Xiao-Chai-Hu-Tang) and crude saikosaponins inhibit hepatitis B virus in a stable HBV-producing cell line[J]. The American journal of Chinese medicine (1979), 2007,35(2): 341. [63] 宋艳玲, 任萌, 周凌竹, 等. 甘草酸及其衍生物抗病毒研究进展[J]. 沈阳药科大学学报, 2023,40(12): 1703-1712. [64] ZHANG N, WANG M, GAO L, et al. Anti-HIV activity in traditional Chinese medicine: clinical implications of monomeric herbal remedies and compound decoctions[J]. Front Med (Lausanne), 2024,11: 1322870. [65] 杨莉. 复方黄芪颗粒联合拉米夫定治疗慢性乙型病毒性肝炎临床研究[J]. 中医学报, 2013,28(04): 579-580.

点击下载PDF